NEW YORK--(BUSINESS WIRE)--Sep. 3, 2020--
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September:
Citi 15th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10, 2020, IVERIC bio will host meetings with investors.
Cantor Virtual Global Healthcare Conference 2020 on Wednesday, September 16, 2020 at 8:00 a.m. ET, investors and the general public are invited to listen to a live webcast of a fireside chat with Glenn P. Sblendorio, Chief Executive Officer and President and Pravin U. Dugel, M.D., Chief Strategy and Business Officer, available on the Investors / Events section of the IVERIC bio website at www.ivericbio.com. An archived replay will be available on the Company’s website immediately following the conference and for at least two weeks thereafter.
The Company will also participate in the following retina showcase:
Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase on Thursday, September 10, 2020 at 1:36 p.m. ET. Dr. Dugel will present an overview of the Company. To listen to the presentation visit the Investors / Events section of the IVERIC bio website at www.ivericbio.com.
About IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005119/en/
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
Alex Van Rees, 973-442-1555 ext. 111
Source: IVERIC bio, Inc.